World Briefs

摘要

Kyowa HakkoKogyo Coi(Tokyp) and Amgen (Thousand Oaks, CA) entered a licensing agreernentunrfer which Amgen will receive an exclusive license to develop and commercialize Kyowa Hakko's humanized monoclonal antibody KW-0761 worldwide, except in Japan, Korea,China and Taiwan.Kyowatlakko will retain rights in these countries.